The US FDA has approved the first generic liraglutide injection to improve glycemic control in adults and pediatric patients aged ten years and older with type 2 diabetes. Clinical evidence Liraglutide has been proven to significantly reduce HbA1c levels in adult (n = 746) and pediatric (n = 134) type 2 diabetes patients at weeks 52 and 26, respectively.
Dosage and administration Once daily subcutaneous injection Administer as an adjunct to diet and exercise Contraindications Personal or family history of medullary thyroid carcinoma Patients with multiple endocrine neoplasia syndrome type 2 Hypersensitivity reaction to liraglutide or any of the product components Warnings and precautions Risk of thyroid C-cell tumors Pancreatitis Hypoglycemia Acute kidney injury Hypersensitivity reactions Acute gallbladder disease Pulmonary aspiration during general anesthesia or deep sedation…
